Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Proposal for changes to the process of including new diseases in newborn screening in Norway

On June 26, 2024, the Norwegian Directorate of Health published its proposal to change the process of including new diseases (or removing existing ones) in newborn screening. The key objective is making the process more dynamic, which requires regulatory and administrative amendments.

The key proposed changes are the following:

  • The reference group for the newborn screening will receive a more explicit mandate to assess the knowledge base and provide professional support and recommendations on whether the disease should be included in the screening program;
  • Applications for the inclusion (or removal) of diseases to the screening program must be submitted through regional health authorities (RHA); 
  • The newborn screening will continue to be a national service according to specialist health services regulations;
  • Changes are proposed in the regulations for genetic testing;
  • The timelines for various stages of the process are to be set.

No changes are planned for the criteria that the Directorate of Health uses to assess applications for introducing new diseases in the screening or removing existing diseases, as well as for evidence requirements.

See the full details in Norwegian here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.